ArticleThe journal of allergy and clinical immunology. Global2026
Impact of prednisolone tapering and extended dupilumab dosing intervals on comorbid asthma in patients with chronic rhinosinusitis with nasal polyps.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently coexists with asthma and involves type 2 inflammation. Dupilumab enables prednisolone (PSL) tapering and extended dosing intervals in CRSwNP, but the impact on comorbid asthma is unclear. Objectives: We evaluated the impact of PSL tapering and extended dupilumab dosing intervals on asthma outcomes in patients with CRSwNP. Methods: We retrospectively analyzed 60 patients with CRSwNP and comorbid asthma treated with dupilumab between 2020 and 2023 who reduced oral PSL to ≤1 mg within 1 year on dupilumab administered every 2 weeks and then extended the dosing interval to ≥3 weeks. Airway outcomes including nasal polyp score, CT score, olfactory function, asthma control test, spirometry, oscillometry, fractional exhaled nitric oxide, blood eosinophils, serum IgE, and annual exacerbation frequency were assessed at baseline, 3 months, and annually up to 3 years. Results: Nasal polyp score, CT score, asthma control test and fractional exhaled nitric oxide improved within 3 months and remained stable during PSL tapering and interval extension. Forced expiratory volume in 1 second and R5 improved transiently but gradually returned toward baseline over time. Eosinophil counts rose after PSL tapering but subsequently declined despite reduced dupilumab frequency. Total IgE and exacerbation frequency remained consistently suppressed. Subgroup analyses showed that asthma control improved or remained well controlled irrespective of baseline severity or step-down in asthma treatment. Conclusions: In patients with CRSwNP and comorbid asthma, PSL tapering and extension of dupilumab dosing intervals were feasible and did not worsen asthma control when sinonasal disease remained well controlled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.